# Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

> **NCT00019968** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)**

## Conditions studied

- Stage IVB Adult Soft Tissue Sarcoma
- Stage IIB Adult Soft Tissue Sarcoma
- Stage IIC Adult Soft Tissue Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Stage IVA Adult Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** melphalan
- **DRUG:** tumor necrosis factor

## Key facts

- **NCT ID:** NCT00019968
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** 2002-03
- **Target enrollment:** — (—)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019968, "Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00019968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*